2nd Sep 2008 11:04
Tepnel Life Sciences plc ("Tepnel" or the "Company")
Additional Listing and TVR
Manchester, UK - 2 September 2008: Tepnel Life Sciences PLC (AIM: TED), the UK-based international Molecular Diagnostics and Research Products & Services group, was informed that 669,100 warrants have been converted by warrantholders into new ordinary shares of 1p each ("New Ordinary Shares") at an exercise price of 6.98p per share.
The New Ordinary Shares have been issued and allotted as fully paid up and rank pari passu in all respects with the existing issued ordinary share capital of the Company.
Application has been made by the Company for the admission of the 669,100 New Ordinary Shares to be admitted to the AIM market. It is expected that Admission will become effective and that dealings in the New Ordinary Shares on AIM will commence on 8 September 2008.
Following Admission of the New Ordinary Shares, the total number of ordinary shares in issue and therefore the total number of voting rights will be 230,880,575.
For Further Information:
Tepnel Life Sciences plc
Ben Matzilevich, CEO
Michael Slater, Group Finance Director
Carol Smith, Group Marketing Communications Manager
0161 946 2200
Capital MS&L
Mary Clark or Joey Whineray
Tel: +44 20 7307 5330
Seymour Pierce Limited
Mark PercyTel: +44 20 7107 8000
Notes to Editors
About Tepnel Life Sciences plc
Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services group with two main divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France over 200 employees. Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and Biomedical Research. The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets. Tepnel focuses on these niche opportunities with internally developed products, patents, expertise and know-how as well as strategic acquisitions, to develop a leadership position within these defined market segments.
Related Shares:
TED.L